Core Insights - Veeva Systems, Inc. reported adjusted earnings per share (EPS) of $2.04 for Q3 fiscal 2026, a 16.6% increase from $1.75 year-over-year, surpassing the Zacks Consensus Estimate by 4.62% [1] - Total revenues for the quarter reached $811.2 million, exceeding the Zacks Consensus Estimate by 2.4% and reflecting a 16% year-over-year growth [2] Revenue Details - Subscription services revenues rose 17.5% year-over-year to $682.5 million, driven by both established and new solutions, compared to an estimate of $671 million [3] - Professional services and other revenues increased 13% year-over-year to $128.7 million, surpassing the estimate of $120.1 million [4] Margin Performance - Gross profit improved 16.6% year-over-year to $611.8 million, with a gross margin expansion of 30 basis points to 75.4%, slightly above the predicted 75.3% [5] - Operating profit totaled $240.9 million, a 32.8% increase from the prior year, with an operating margin expansion of 380 basis points to 29.7%, exceeding the predicted 26.7% [7] Financial Position - At the end of Q3 fiscal 2026, the company had cash and cash equivalents and short-term investments of $6.64 billion, up from $6.40 billion at the end of Q2 [8] - Cumulative net cash provided by operating activities was $1.31 billion, compared to $1.02 billion a year ago [8] Guidance - For Q4 fiscal 2026, Veeva expects total revenues between $807 million and $810 million, with subscription revenues estimated at approximately $696 million [11] - The company raised its fiscal 2026 revenue outlook to between $3,166 million and $3,169 million, up from previous guidance of $3,134 million to $3,140 million [12] - Adjusted EPS for fiscal 2026 is now expected to be $7.93, an increase from the previous guidance of $7.78 [14] Strategic Developments - Veeva AI achieved significant milestones during Q3, with plans to release AI agents for CRM and commercial content in early December, and additional agents for R&D and quality in development for 2026 [16][18] - The company strengthened its leadership in CRM, adding 23 new customers, including a major rollout for a top-20 biopharma company in Japan [19] - Veeva Development Cloud saw three top-20 biopharma companies select its applications as their enterprise standard, indicating rising industry confidence [20]

Group 1: Elastic NV Performance - Elastic NV reported second-quarter adjusted earnings of 64 cents per share, exceeding the analyst estimate of 58 cents [1] - The company's quarterly revenue was $423.48 million, surpassing the Street estimate of $418.16 million [1] - Despite the positive earnings and revenue results, Elastic shares fell 12.3% to $72.02 in pre-market trading [1] Group 2: Other Stocks in Pre-Market Trading - Luda Technology Group Ltd experienced an 11.1% decline to $8.55 after a 39% gain on Thursday [4] - AnaptysBio Inc fell 9.7% to $34.00 following the announcement of a $100 million stock repurchase plan [4] - Sigma Lithium Corp decreased by 8.4% to $8.61 after a 9% decline on Thursday [4] - Veeva Systems Inc saw a 6.7% drop to $252.40 despite posting upbeat third-quarter results and raising fiscal year earnings and revenue estimates [4] - American Bitcoin Corp declined 6.3% to $4.29 in pre-market trading [4] - Standard Lithium Ltd fell 6.3% to $3.60 [4] - Indivior PLC declined 5.9% to $29.90 after settling a matter with the U.S. Department of Justice for $295 million [4] - HIVE Digital Technologies Ltd dropped 5.8% to $2.75 after filing for mixed shelf [4] - Albemarle Corp fell 5.5% to $109.99 [4] - Oncology Institute Inc decreased by 2.1% to $3.17 [4]

Core Insights - The software company has raised its fiscal-year guidance, indicating positive growth expectations despite challenges in the earnings call commentary [1] Group 1: Fiscal-Year Guidance - The company has increased its fiscal-year guidance, suggesting a strong outlook for revenue and profitability [1] - This adjustment reflects confidence in the company's operational performance and market conditions [1] Group 2: Earnings Call Commentary - The commentary from the earnings call has overshadowed the positive guidance, indicating potential concerns or issues raised during the discussion [1] - Analysts and investors may focus on the earnings call details, which could impact market perception despite the improved guidance [1]

Market Overview - U.S. stock futures showed volatility with mixed performance after a significant sell-off on Thursday, with the S&P 500 index dropping below key support levels [1][2] - The S&P 500 index fell below its 50-day moving average for the first time in months, indicating potential bearish sentiment [1] Economic Indicators - September's job report revealed non-farm payrolls increased by 119,000, significantly exceeding the forecast of 50,000, which dampened expectations for interest rate cuts [2] - The 10-year Treasury bond yield was at 4.08%, while the two-year bond yield stood at 3.53%, reflecting market sentiment on interest rates [2] Futures Performance - Dow Jones futures increased by 0.28%, while S&P 500 and Nasdaq 100 futures decreased by 0.14% and 0.47%, respectively [3] - The SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ Trust ETF (QQQ) both experienced declines in premarket trading, with SPY down 0.35% and QQQ down 0.77% [3] Company Highlights - New Fortress Energy Inc. surged by 19.86% due to successful debt restructuring efforts [5] - Gap Inc. advanced by 3.86% after reporting strong third-quarter results and raising its FY25 sales guidance [5] - Veeva Systems Inc. saw a decline of 6.69% despite positive third-quarter results and raised fiscal year estimates [4][5] - Elastic NV dropped by 12.21% despite a solid earnings beat and strong guidance for the current quarter [5] - Intuit Inc. rose by 3.23% after reporting better-than-expected first-quarter results, although it expects second-quarter adjusted earnings to be below estimates [14] Analyst Insights - Scott Wren from Wells Fargo Investment Institute maintains a bullish outlook for the equity market through 2026, forecasting an accelerating economy driven by deregulation and expected Federal Reserve rate cuts [10][11] - Wren suggests reallocating investments from fully valued technology sectors into Financials and Industrials, which are expected to benefit from AI infrastructure growth [12]

Market Overview - U.S. stock futures showed volatility with mixed performance after a significant sell-off on Thursday, with the S&P 500 index dropping below the support line of 6,550 and its 50-day moving average for the first time in months [1][2] - The September job report revealed non-farm payrolls increased by 119,000, exceeding economists' expectations of 50,000, impacting market expectations for interest rate cuts [2] Futures Performance - Dow Jones futures increased by 0.28%, while S&P 500 and Nasdaq 100 futures decreased by 0.14% and 0.47%, respectively [3] - The SPDR S&P 500 ETF Trust (SPY) fell by 0.35% to $650.25, and the Invesco QQQ Trust ETF (QQQ) declined by 0.77% to $581.15 in premarket trading [3] Stocks in Focus - New Fortress Energy Inc. surged by 19.86% due to debt restructuring efforts, while Gap Inc. rose by 3.86% after positive third-quarter results and an increase in FY25 sales guidance [4][5] - Veeva Systems Inc. dropped by 6.69% despite strong quarterly results and raised fiscal year estimates, while Elastic NV fell by 12.21% despite a solid earnings beat and strong guidance [4][5] Analyst Insights - Scott Wren from Wells Fargo Investment Institute maintains a bullish outlook for the equity market through 2026, forecasting an accelerating economy driven by deregulation and expected Federal Reserve rate cuts [10][11] - Wren advises reallocating investments from fully valued technology sectors into Financials and Industrials, which are expected to benefit from AI infrastructure growth [12] Upcoming Economic Data - Investors are anticipating key economic data releases, including November's S&P flash U.S. services and manufacturing PMI and final consumer sentiment data [15]

Core Insights - Veeva Systems reported a revenue of $811.24 million for the quarter ended October 2025, reflecting a 16% increase year-over-year and surpassing the Zacks Consensus Estimate of $791.88 million by 2.44% [1] - The company's EPS for the quarter was $2.04, up from $1.75 in the same quarter last year, exceeding the consensus EPS estimate of $1.95 by 4.62% [1] Revenue Breakdown - Subscription services revenue reached $682.5 million, exceeding the average estimate of $671.02 million, with a year-over-year growth of 17.5% [4] - Professional services and other revenue totaled $128.74 million, surpassing the average estimate of $120.86 million, marking an 8.8% increase year-over-year [4] - Veeva R&D Solutions generated $81.28 million in revenue, exceeding the average estimate of $74.66 million, representing a 12.1% year-over-year increase [4] - Subscription services from Veeva R&D Solutions amounted to $364.85 million, above the average estimate of $361.28 million, with a year-over-year growth of 20.6% [4] - Veeva Commercial Solutions' subscription services revenue was $317.65 million, exceeding the average estimate of $309.72 million, reflecting a 14.1% increase year-over-year [4] - Professional services and other revenue from Veeva Commercial Solutions reached $47.46 million, surpassing the average estimate of $46.26 million, with a year-over-year change of 3.5% [4] Margin Analysis - Non-GAAP Gross Margin for Professional services and other was reported at 29.8%, below the average estimate of 31.8% [4] - Non-GAAP Gross Margin for Subscription services was 86.6%, slightly above the average estimate of 85.9% [4] Stock Performance - Veeva's shares have returned -5.8% over the past month, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Veeva Systems reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.95 per share, and up from $1.75 per share a year ago [1][2] - The company achieved revenues of $811.24 million for the quarter, surpassing the Zacks Consensus Estimate by 2.44% and increasing from $699.21 million year-over-year [3] - Veeva has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2][3] Earnings Performance - The earnings surprise for the recent quarter was +4.62%, following a previous surprise of +4.74% [2] - The current consensus EPS estimate for the upcoming quarter is $1.87, with expected revenues of $798.22 million, while the estimate for the current fiscal year is $7.78 on $3.14 billion in revenues [8] Stock Performance - Veeva shares have increased approximately 29.8% since the beginning of the year, compared to a 12.9% gain for the S&P 500 [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Industry Outlook - The Medical Info Systems industry, to which Veeva belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook [9] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [6]

Financial Data and Key Metrics Changes - Total revenue for Q3 was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [6] - CRM now constitutes about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [9] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative, with significant progress expected to benefit customers and the industry [6] - Crossix continues to perform well, with expectations for it to remain a growth driver in the coming years [34][39] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong, with no significant changes in customer buying behaviors noted [31] - Digital marketing spending is increasing, which positively impacts Crossix's business [39] Company Strategy and Development Direction - The company is focused on delivering integrated solutions across clinical operations and clinical data to drive efficiency [11] - Veeva aims to leverage its consulting, data, and software capabilities to provide comprehensive solutions for life sciences [47][48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the industry, citing ongoing demand for innovative solutions to address uncured diseases [31] - The company anticipates no material impact on its 2030 goals despite some customer attrition in the CRM segment [9][75] Other Important Information - The company is investing in product and services teams, which may impact margins in the short term but is expected to yield positive results over time [58] - The partnership with IQVIA is seen as beneficial, enhancing customer confidence and operational capabilities [41][42] Q&A Session Summary Question: Concerns about CRM customer migration - Management acknowledged that CRM is about 20% of total revenue and that attrition is expected to have no immediate impact on 2030 goals [9][75] Question: Competitive landscape in EDC market - Management noted that while one customer returned to a previous provider, overall trends in clinical remain positive with opportunities for growth [11] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry is cautious about making significant changes [28] Question: Demand environment in pharma - Management reported that the industry is healthy, with no significant changes in customer buying behaviors despite external political factors [31] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver moving forward [34][39] Question: Quality cloud expansion - Management highlighted that the quality cloud opportunity is expanding through reaching new customer types and product expansion [80]

Financial Data and Key Metrics Changes - Total revenue for Q3 was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [6] - CRM now constitutes about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [9] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative with significant progress, expected to add value across various product areas including Vault CRM, Crossix, clinical, and safety [6] - Crossix continues to perform well, with expectations for it to remain a growth driver in the coming years [34] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong despite political chaos, with no significant changes in customer buying behaviors noted [31] - Digital marketing spending is increasing, which benefits Crossix as it becomes a standard for measurement and optimization [39] Company Strategy and Development Direction - The company is focused on delivering integrated solutions across clinical operations and clinical data, emphasizing efficiency as a key driver [11] - Veeva aims to be a comprehensive provider in the life sciences sector, integrating software, data, and consulting services [47] Management's Comments on Operating Environment and Future Outlook - Management expresses optimism about the industry, citing ongoing demand for innovative solutions to address uncured diseases [31] - The company anticipates no material impact on its 2030 goals despite some customer attrition in the CRM segment, as the business is diverse and has multiple growth paths [75][76] Other Important Information - The company is investing in product and services teams, with a focus on business consulting and professional services to enhance customer engagement [59] - The partnership with IQVIA is seen as a positive trend, enhancing customer confidence and operational capabilities [42] Q&A Session Summary Question: Concerns about CRM customer migration - Management noted that CRM is currently about 20% of total revenue, down from 25% two years ago, and emphasized that no immediate impact is expected from customer migrations [9][19] Question: Competitive landscape in EDC market - Management acknowledged a competitor winning back a top 20 customer but expressed confidence in their own pipeline and opportunities in the EDC market [10][11] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry remains cautious about significant changes due to the need for relationship building [28] Question: Demand environment and financial health of pharma market - Management reported that the pharmaceutical industry is healthy, with no significant changes in demand or buying behavior observed [31] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver in the future [34][70] Question: Insights from customer-specific factors affecting CRM wins - Management stated that customer-specific dynamics are at play, with no overarching pattern, and emphasized the health of the overall CRM business [56][57]

Financial Data and Key Metrics Changes - Total revenue for the quarter was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [5] - CRM revenue has decreased to about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [8] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative, with significant progress expected to benefit customers and the industry [5] - Crossix continues to perform well, contributing to overall revenue growth, with expectations for it to remain a strong growth driver [32][37] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong, with no significant changes in customer buying behaviors noted [28] - Digital marketing spending is increasing, which positively impacts Crossix's performance and growth potential [36] Company Strategy and Development Direction - The company is focused on integrating its software, data, and consulting services to provide comprehensive solutions for life sciences [44] - There is an emphasis on innovation in clinical and safety areas, with expectations for AI to drive efficiency and effectiveness [19][48] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the industry, citing ongoing demand for solutions to uncured diseases and a stable market environment [28] - The company expects to continue to meet its 2030 goals despite some customer attrition in the CRM segment, due to the diverse nature of its business [73] Other Important Information - The company is investing in hiring for product and services teams to support growth and innovation [55] - The partnership with IQVIA is seen as beneficial, enhancing customer confidence and providing opportunities for joint solutions [40] Q&A Session Summary Question: Concerns about CRM customer migration - Management acknowledged that CRM is currently about 20% of total revenue and that attrition is not expected to impact long-term goals [8][73] Question: Competitive landscape in EDC market - Management noted that while one customer returned to a previous provider, overall trends in clinical operations remain positive, with opportunities for growth [10] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry is cautious about making significant changes [26] Question: Demand environment in pharma - Management reported that the industry is healthy, with no significant changes in customer buying behaviors despite political and economic challenges [28] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver moving forward [32][37] Question: Balancing go-to-market initiatives - Management stated that dedicated teams are in place to focus on various product areas, allowing for simultaneous advancement in multiple initiatives [68]